急性缺血性脑卒中防治策略研究进展  

Research Progress in Prevention and Treatment Strategy of Acute Ischemic Stroke

作　　者：宁珑 孙航 冯晋 宋雪兰 何芳雁 NING Long;SUN Hang;FENG Jin;SONG Xuelan;HE Fangyan(College of Traditional Chinese Medicine,Yunnan University of Chinese Medicine,Kunming 650500,China)

机构地区：[1]云南中医药大学中药学院,昆明650500

出　　处：《医学综述》2022年第1期94-99,共6页Medical Recapitulate

基　　金：国家自然科学基金(81660677);云南省科技厅科技计划项目〔2018FF001(-074),202001AT070138,202101AT070264〕。

摘　　要：急性缺血性脑卒中(IS)对人类健康造成巨大影响,其病理过程复杂,目前缺乏安全有效的治疗手段。当前IS的治疗仍以治疗时间窗内进行组织型纤溶酶原激活物溶栓为主,但易受时间窗较窄的限制;神经保护剂于临床前研究虽有较佳效果,但在临床研究中无明显疗效;而通过预防IS的致病因素达到降低IS的发生风险可能为防治最佳策略,但存在药物使用不合理及患者依从性较差的问题。因此,延长溶栓时间窗、优化神经保护剂的使用和临床转化、规范预防药物的使用、提高预防IS的高致病因素意识将成为今后IS研究的新方向。Acute ischemic stroke(IS)has a huge impact on human health,and its pathological process is complex,while there is so far no safe and effective treatment.At present,the treatment of IS is still dominated by tissue plasminogen activator thrombolysis within the treatment time window,but it is easily limited by the narrow time window.Neuroprotective agents have shown good effects in preclinical studies,but no significant effect in clinical studies.It seems to be the best strategy to reduce the risk of IS by preventing the pathogenic factors of IS,but there are problems of unreasonable drug use and poor patient compliance.Therefore,extending the thrombolysis time window,optimizing the use and clinical transformation of neuroprotective agents,standardizing the use of preventive drugs,and improving the awareness of high risk factors for IS prevention will be new directions of IS research in the future.

关 键 词：缺血性脑卒中 溶栓治疗 神经保护治疗 危险因素 脑缺血预后 

分 类 号：R743.3[医药卫生—神经病学与精神病学]